Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > UK online pharmacy Rightangled still selling diabetes drug Ozempic despite govt order
    Top Stories

    UK online pharmacy Rightangled still selling diabetes drug Ozempic despite govt order

    Published by Jessica Weisman-Pitts

    Posted on October 20, 2023

    3 min read

    Last updated: January 31, 2026

    This image shows Ozempic pens on a production line at Novo Nordisk's facility, highlighting the diabetes medication linked to weight loss. Despite government restrictions, UK pharmacy Rightangled continues to offer Ozempic to consumers.
    Ozempic diabetes treatment pens on a production line - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:healthcareUK economyRegulatory Compliance

    UK online pharmacy Rightangled still selling diabetes drug Ozempic despite govt order

    By Maggie Fick

    LONDON (Reuters) – UK private online pharmacy Rightangled was offering Novo Nordisk’s diabetes drug Ozempic for sale on Friday to people wanting to use the weekly injection to shed pounds, its website shows, even after a government order to stop doing so.

    Ozempic is licensed in the UK for managing blood sugar levels in people with type 2 diabetes. However, last year, many people who don’t have diabetes turned to Ozempic as a slimming jab, using online pharmacies prescribing it “off-label”.

    In July, the Department of Health and Social Care (DHSC) and Britain’s National Health Service declared a national shortage of Ozempic and all other drugs in a class called “GLP-1 receptor agonists” due to the soaring demand for approved and off-label use.

    It warned the shortage will last until at least mid-2024.

    It also instructed doctors and other prescribers, like private online pharmacies, to stop prescribing Ozempic to people who don’t have type 2 diabetes as soon as possible and not later than Oct. 18. It also banned prescribers from starting new patients with type 2 diabetes on the medicine for as long as the shortage lasts.

    The Rightangled offers to ship the drug were displayed on the pharmacy’s website on Friday under its “general health: weight loss” section noting it was for “diabetes management but can aid in weight loss as off label.”

    Rightangled, a UK-based online pharmacy chain, and DHSC did not immediately respond to requests for comment.

    On Thursday, Rightangled, a privately owned and UK-registered pharmacy that delivers prescription medicines to customers that place online orders, offered to supply Ozempic to one of its customers in an email reviewed by Reuters.

    “Grab yours before it’s gone again,” the email which was dated Oct. 19 and shared with Reuters by the customer says, including a photograph of an Ozempic pen in a box.

    Reuters on Friday checked the websites of other private online pharmacies that have prescribed Ozempic this year for weight-loss.

    One of them, Farmeci, lists only Wegovy and Saxenda, another Novo Nordisk medicine that like Wegovy is approved for weight-loss, under its weight-loss treatments section.

    Another, Juniper, a venture capital-backed private online clinic, refers on its site to Ozempic as a medicine “licensed to treat diabetes in the UK”.

    A third, Simple Online Pharmacy, mentions this in its description of Ozempic: “Because Ozempic is primarily a drug used in diabetes, we choose not to prescribe this, so as not to affect critical supply chains for diabetic patients.”

    (Reporting by Maggie Fick; Editing by Josephine Mason and Susan Fenton)

    Frequently Asked Questions about UK online pharmacy Rightangled still selling diabetes drug Ozempic despite govt order

    1What is a GLP-1 receptor agonist?

    GLP-1 receptor agonists are a class of medications that help lower blood sugar levels by enhancing insulin secretion and slowing gastric emptying.

    2What is a national shortage in pharmaceuticals?

    A national shortage occurs when the demand for a medication exceeds its supply, leading to limited availability for patients who need it.

    3What is regulatory compliance?

    Regulatory compliance involves adhering to laws, regulations, guidelines, and specifications relevant to an organization's business processes.

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostAnalysis-Middle East throws central banks yet more unknowns
    Next Top Stories PostRed October rumbles on as U.S. bond yields touch 5%